<DOC>
	<DOCNO>NCT02863354</DOCNO>
	<brief_summary>The RECOVERY trial ass safety tolerability 2 mg intravitreal aflibercept injection ( IAI ) give monthly ( Q4WK ) every 12 week ( Q12WK ) treatment retinal non-perfusion ( RNP ) associate proliferative diabetic retinopathy ( PDR ) primarily assess retinal capillary non-perfusion .</brief_summary>
	<brief_title>Intravitreal Aflibercept Retinal Non-Perfusion Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description>The investigational product intravitreal aflibercept injection , supply Regeneron Pharmaceuticals , Inc. sterile vial intravitreal ( IVT ) injection . Vials must use ( define enter needle ) . All drug supply keep recommended storage condition . The injection volume 50μL ( 0.05 mL ) administer subject IVT injection . Study eye assign randomly ( 1:1 ratio ) one follow 2 treatment arm : - Q4WKS- aflibercept 2 mg every 4 week ( define every 28 day + 7 day least 21 day injection ) . - Q12WKS- aflibercept 2 mg every 12-weeks . Subjects follow every 4 week week 12 , treat pre-specified criterion meet . Starting week 12 NV PDR stable improve ( assessed investigator ) subject monitor treated 12-week interval . If NV ( neovascularization ) PDR bad per pre-specified criterion week 12 , study visit thereafter , subject treat monthly end study . Pre-specified criterion ( subject must meet least one criterion must document image ) : 1 . Increased neovascularization 2 . Decrease BCVA 5 letter due progressive DME ( diabetic macular edema ) PDR 3 . Worsening central subfield diabetic macular edema cause vision loss , principal investigator delegate investigator confirmation 4 . Total area retinal ischemia increase 10 % determined central reading center Rescue Treatment At point throughout study , either treatment arm , PDR progress despite 3 monthly IAI , fluorescein angiogram perform evaluate PDR progression . PRP permit confirmation PDR progression primary</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>1 . Type 1 type 2 diabetes mellitus 2 . BCVA ETDRS &gt; 20/400 study eye 3 . Willing able comply clinic visit studyrelated procedure 4 . Provide sign informed consent 5 . Substantial non perfusion ( define great 20 disc area ) , assess investigator 6 . Early PDR , assess investigator , vitreous hemorrhage* Early PDR define PRP safely defer vitreous hemorrhage obscure application PRP 1 . Any prior systemic antiVEGF ( anti vascular endothelial growth factor ) IVT antiVEGF treatment study eye , 2 . SDOCT ( Spectral Domain Optical Coherence Tomography ) central subfield thickness measurement &gt; 320 µm , study eye 3 . Evidence infectious ocular infection , study eye , time screen 4 . History vitreoretinal surgery study eye 5 . Any prior Panretinal laser photocoagulation ( PRP ) study eye 6 . Current vitreous hemorrhage obscure retinal imaging study eye 7 . Cataract surgery study eye within 4 week Day 0 8 . Uncontrolled blood pressure ( define &gt; 180/110 mm Hg systolic/diastolic , seat ) 9 . Significant renal disease define history chronic renal failure require dialysis renal transplant 10 . Tractional Retinal Detachment threaten macula study eye 11 . Corticosteroid treatment ( intravitreal peribulbar ) study eye within 12 week screen 12 . Pregnant breastfeed woman 13 . Sexually active men* woman childbearing potential unwilling practice adequate contraception study . Adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device ( IUD ) ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly . Contraception require men document vasectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>